ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on January 30, 2026. The filing discloses the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Offering Details
The Company entered into an underwriting agreement to raise capital through the sale of common stock and pre-funded warrants. Key metrics include:
- Common Stock Issued: 76,979,112 shares at an offering price of $1.57 per share.
- Pre-Funded Warrants Issued: 18,574,120 warrants at an offering price of $1.569 per warrant.
- Warrant Exercise Price: $0.001 per share.
- Gross Proceeds: Approximately $150 million (before underwriting discounts, commissions, and offering expenses).
- Expected Closing Date: February 2, 2026.
- Underwriters: Piper Sandler & Co., UBS Securities LLC, and Wells Fargo Securities, LLC.
The filing does not provide current revenue, profit, cash flow, or debt figures as this is a transactional report rather than a periodic financial statement.
Material Changes and Unusual Items
The primary material change is the significant dilution of existing shareholders resulting from the issuance of approximately 95.5 million new equity instruments (shares and warrants). The offering is being made pursuant to an effective registration statement on Form S-3 (File No. 333-285620).
Guidance, Outlook, and Risks
Management has not provided specific operational guidance in this filing. The report includes forward-looking statements regarding the timing and completion of the offering. Key risks and contingencies include:
- Failure to satisfy customary closing conditions.
- Market conditions affecting the completion of the public offering.
- Ownership limitations on Pre-Funded Warrants, restricting exercise if it causes beneficial ownership to exceed 4.99% or 9.99% (adjustable up to 19.99% with notice).
- Reference to "Risk Factors" in the Company's Form 10-Q filed on November 7, 2025, for a comprehensive list of uncertainties.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Review the Form 10-Q filed on November 7, 2025, to assess current liquidity and cash runway relative to the new capital raised.
- Confirm the exact number of shares outstanding post-closing to calculate the dilution impact on existing shareholders.
- Examine the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.